News
News
- GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
01/11/2022 / 13:12 - GlobeNewswire - Omicron might behave differently in US - Fauci
12/22/2021 / 21:36 - TeleTrader - Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
12/17/2021 / 14:16 - GlobeNewswire - Sanofi, GSK virus booster shot data in early 2022
12/15/2021 / 11:24 - TeleTrader - GSK-Vir COVID-19 drug effective vs. Omicron - data
12/07/2021 / 12:24 - TeleTrader - Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
12/07/2021 / 09:48 - GlobeNewswire - UK approves GSK antibody COVID-19 drug
12/02/2021 / 08:53 - TeleTrader - GSK: Antibody treatment works against Omicron
12/02/2021 / 08:20 - TeleTrader - Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
12/02/2021 / 08:07 - GlobeNewswire - Pfizer vaccine executive to join GSK
11/30/2021 / 14:22 - TeleTrader
Real-time